60 Degrees Pharmaceuticals (Nasdaq: SXTP), specialists in developing and marketing medicines for infectious diseases, announced that the United States Patent and Trademark Office (USPTO) has awarded 60P a patent covering the use of tafenoquine for prevention of Plasmodium falciparum malaria. Tafenoquine is the active molecule in ARAKODA®, the Company’s FDA-approved drug for malaria prevention in individuals aged 18 years and older for up to six months of continuous dosing.

Splash Beverage (NYSE American: SBEV), a portfolio company of leading beverage brands, announced it has entered new or expanded distribution agreements with Chicago’s Lakeshore Beverage, Mississippi’s Southern Beverage Company, and Georgia’s United Distributors. At the same time, Splash announced that Copa di Vino will now be offered in nine Blaze Pizza locations across Southern California. Splash Beverage also announced that one of the nation’s fastest growing pizza chains, Blaze Pizza, will carry Copa di Vino in nine locations across Southern California.

SPI Energy (Nasdaq: SPI), a global renewable energy company and provider of solar storage and electric vehicle (EV) solutions for business, residential, government, logistics and utility customers, announced its financial results for the second quarter ended June 30, 2023. "I am proud to report that SPI Energy has delivered another exceptional quarter of performance, demonstrating our continued ability to drive growth and improve profitability," said Xiaofeng Peng, Chairman and Chief Executive Officer of SPI Energy. "Our net sales grew by 21.1% to $58.9 million, while our gross profit increased by 35.3% to $5.2 million, reflecting the robustness of our operations and the effectiveness of our strategies. It is important to note that our net loss includes a $3.18 million operating loss from our subsidiary, Phoenix Motor Inc., which we spun out into a separate entity on the Nasdaq in 2022. Excluding this, SPI Energy's operations have passed the breakeven point, underscoring the strength of our core business lines.”

Soligenix (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced its recent accomplishments and financial results for the quarter ended June 30, 2023. "During the second quarter we advanced multiple clinical trials, while continuing our collaborative discussions with the U.S. Food and Drug Administration (FDA) regarding the design of a second, confirmatory Phase 3 pivotal study evaluating HyBryte™ (synthetic hypericin sodium) in the treatment of cutaneous T-cell lymphoma (CTCL), where we successfully demonstrated statistically significant results in the first Phase 3 clinical trial," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. “With approximately $13.2 million in cash at June 30, 2023, we are managing cash burn very carefully in order to achieve our near-term milestones, as we continue to assess all strategic options, including but not limited to, partnership and merger and acquisition opportunities.”